Metabolic Risk Factors Linked to Severe Liver Disease

This article originally appeared here.
Share this content:
Metabolic Risk Factors Linked to Severe Liver Disease
Metabolic Risk Factors Linked to Severe Liver Disease

THURSDAY, Dec. 7, 2017 (HealthDay News) -- Metabolic risk factors are associated with severe liver disease, according to a study published online Nov. 22 in Hepatology.

Fredrik Åberg, M.D., Ph.D., from Helsinki University Hospital in Finland, and colleagues examined metabolic factors that predict severe liver complications, stratified by alcohol consumption, for a nationally representative cohort of 6,732 individuals without baseline liver disease. Follow-up data through 2013 were analyzed for liver-related admissions, mortality, and liver cancer.

The researchers found that 84 individuals experienced a severe liver event during follow-up. Factors that significantly predicted liver events in the final multivariate model were age (hazard ratio, 1.02), gender (women: hazard ratio, 0.55), alcohol use (hazard ratio, 1.002), diabetes (hazard ratio, 2.73), low-density lipoprotein cholesterol (LDL-C: hazard ratio, 0.74), and homeostatic model assessment of insulin resistance (HOMA-IR: hazard ratio, 1.01). Diabetes was the only significant predictor among alcohol risk users (hazard ratio, 6.79). Significant independent predictors among non-risk drinkers were age, alcohol use, smoking, waist circumference, low LDL-C, and HOMA-IR. Additional predictors were the total cholesterol-to-LDL-C ratio and waist circumference-to-body mass index ratio.

"Multiple components of the metabolic syndrome independently affected the risk for severe liver disease," the authors write. "Alcohol was significant even when average alcohol consumption was within the limits currently defining non-alcoholic fatty liver disease."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »